Last reviewed · How we verify
Androgen Therapy
Androgen therapy works by supplementing or replacing testosterone and other androgens to restore hormonal balance and promote anabolic effects in patients with androgen deficiency.
Androgen therapy works by supplementing or replacing testosterone and other androgens to restore hormonal balance and promote anabolic effects in patients with androgen deficiency. Used for Indication under investigation in Phase 3 oncology trial (specific indication not publicly detailed).
At a glance
| Generic name | Androgen Therapy |
|---|---|
| Sponsor | Alliance for Clinical Trials in Oncology |
| Drug class | Androgen replacement therapy |
| Target | Androgen receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Androgens bind to androgen receptors on target tissues throughout the body, promoting protein synthesis, muscle growth, bone density, and sexual function. In oncology contexts, androgen therapy may be used in specific patient populations or as part of combination regimens, though the exact mechanism in this Phase 3 trial context requires clarification of the specific indication.
Approved indications
- Indication under investigation in Phase 3 oncology trial (specific indication not publicly detailed)
Common side effects
- Polycythemia
- Hepatotoxicity
- Cardiovascular events
- Gynecomastia
- Mood changes
Key clinical trials
- A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss (PHASE2)
- A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer (PHASE1, PHASE2)
- Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment (PHASE3)
- Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer (PHASE2)
- A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma (PHASE2)
- A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) (PHASE1, PHASE2)
- High-Risk prostatE Cancer radiatiOn Versus surgERy
- Polycystic Ovary Syndrome in Type 1 Diabetes
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Androgen Therapy CI brief — competitive landscape report
- Androgen Therapy updates RSS · CI watch RSS
- Alliance for Clinical Trials in Oncology portfolio CI